Moderna reports vaccine remains highly effective through six months
Moderna Inc. today announced during an investors report that its COVID-19 vaccine remains 93% effective through the first six months following a full dosing regimen.
Moderna also reported that, in its effort to earn full Food and Drug Administration approval for the vaccine, it initiated the rolling submission process for a Biologics License Application for the current vaccine in the U.S., a process it expects to complete its submission in August. Moderna also has completed enrollment for a phase 1 clinical trial of a next-generation COVID-19 vaccine that will be refrigerator-stable.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…